Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

Acasti Pharma (ACST) Stock Forecast & Price Target

Acasti Pharma logo
Get the Latest News and Ratings for ACST and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Acasti Pharma and its competitors.

Sign Up

ACST Analyst Ratings Over Time

TypeCurrent Forecast
12/18/23 to 12/17/24
1 Month Ago
11/18/23 to 11/17/24
3 Months Ago
9/19/23 to 9/18/24
1 Year Ago
12/18/22 to 12/18/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$10.00$10.00$6.00$15.00
Forecasted Upside196.74% Upside196.74% Upside120.59% Upside604.23% Upside
Consensus Rating
Buy
Buy
Buy
Buy

ACST Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ACST Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Acasti Pharma Stock vs. The Competition

TypeAcasti PharmaMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.80
2.51
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside196.74% Upside29,882.15% Upside11.82% Upside
News Sentiment Rating
Negative News

See Recent ACST News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/26/2024HC Wainwright
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00+297.35%
9/26/2024Craig Hallum
3 of 5 stars
 Boost TargetBuy ➝ Buy$6.00 ➝ $8.00+173.04%
2/15/2023EF Hutton Acquisition Co. I
1 of 5 stars
 Reiterated RatingBuy$15.00+296.82%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 01:54 PM ET.


ACST Forecast - Frequently Asked Questions

According to the research reports of 2 Wall Street equities research analysts, the average twelve-month stock price forecast for Acasti Pharma is $10.00, with a high forecast of $12.00 and a low forecast of $8.00.

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Acasti Pharma in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACST shares.

According to analysts, Acasti Pharma's stock has a predicted upside of 196.74% based on their 12-month stock forecasts.

Acasti Pharma has been rated by research analysts at Craig Hallum, and HC Wainwright in the past 90 days.

Analysts like Acasti Pharma more than other "medical" companies. The consensus rating for Acasti Pharma is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ACST compares to other companies.


This page (NASDAQ:ACST) was last updated on 12/17/2024 by MarketBeat.com Staff
From Our Partners